SLDB Straddle Strategy
SLDB (Solid Biosciences Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
SLDB (Solid Biosciences Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $575.0M, a beta of 2.47 versus the broader market, a 52-week range of 2.41-8.866, average daily share volume of 1.3M, a public-listing history dating back to 2018, approximately 100 full-time employees. These structural characteristics shape how SLDB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.47 indicates SLDB has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a straddle on SLDB?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current SLDB snapshot
As of May 15, 2026, spot at $6.82, ATM IV 187.70%, IV rank 38.63%, expected move 53.81%. The straddle on SLDB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this straddle structure on SLDB specifically: SLDB IV at 187.70% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 53.81% (roughly $3.67 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SLDB expiries trade a higher absolute premium for lower per-day decay. Position sizing on SLDB should anchor to the underlying notional of $6.82 per share and to the trader's directional view on SLDB stock.
SLDB straddle setup
The SLDB straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SLDB near $6.82, the first option leg uses a $6.82 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SLDB chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SLDB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $6.82 | N/A |
| Buy 1 | Put | $6.82 | N/A |
SLDB straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
SLDB straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on SLDB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on SLDB
Straddles on SLDB are pure-volatility plays that profit from large moves in either direction; traders typically buy SLDB straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
SLDB thesis for this straddle
The market-implied 1-standard-deviation range for SLDB extends from approximately $3.15 on the downside to $10.49 on the upside. A SLDB long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current SLDB IV rank near 38.63% is mid-range against its 1-year distribution, so the IV signal is neutral; the straddle thesis on SLDB should anchor more to the directional view and the expected-move geometry. As a Healthcare name, SLDB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SLDB-specific events.
SLDB straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SLDB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SLDB alongside the broader basket even when SLDB-specific fundamentals are unchanged. Always rebuild the position from current SLDB chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on SLDB?
- A straddle on SLDB is the straddle strategy applied to SLDB (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With SLDB stock trading near $6.82, the strikes shown on this page are snapped to the nearest listed SLDB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are SLDB straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the SLDB straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 187.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a SLDB straddle?
- The breakeven for the SLDB straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SLDB market-implied 1-standard-deviation expected move is approximately 53.81%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on SLDB?
- Straddles on SLDB are pure-volatility plays that profit from large moves in either direction; traders typically buy SLDB straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current SLDB implied volatility affect this straddle?
- SLDB ATM IV is at 187.70% with IV rank near 38.63%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.